Pliant Therapeutics, Inc.
Pliant Therapeutics (Nasdaq: PLRX) is a clinical-stage biopharmaceutical company discovering and developing integrin-based therapeutics. Its lead wholly owned candidate, PLN-101095, is an oral small-molecule inhibitor of αvβ8 and αvβ1 integrins being developed for solid tumors, including tumors resistant to immune… From the company’s description.
In fiscal 2025, Pliant Therapeutics, Inc. reported a net loss of $149.34M. Operations used $128.34M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pliant Therapeutics, Inc. does
In the company’s own words
Pliant Therapeutics (Nasdaq: PLRX) is a clinical-stage biopharmaceutical company discovering and developing integrin-based therapeutics. Its lead wholly owned candidate, PLN-101095, is an oral small-molecule inhibitor of αvβ8 and αvβ1 integrins being developed for solid tumors, including tumors resistant to immune checkpoint inhibitors; the company is also exploring a platform for delivering drug payloads such as siRNAs to selected cell types. Pliant’s proprietary discovery platform includes a library of more than 15,000 integrin-binding molecules and programs targeting delivery to skeletal muscle cells, adipocytes, and renal cells. The company’s earlier candidate bexotegrast was discontinued in development for idiopathic pulmonary fibrosis, while its primary sclerosing cholangitis program remains under evaluation. Pliant conducts drug development and clinical manufacturing through third-party providers and has no marketed products described in its business portfolio. Its website is https://www.pliantrx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1746473
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pliant Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Pliant Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pliant Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pliant Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pliant Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”